Cargando…

Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 Vaccine for COVID-19 Hospitalizations

This comparative effectiveness research study examines the effectiveness of full vaccination with Ad26.COV2.S vs BNT162b2 against COVID-19–related hospitalization.

Detalles Bibliográficos
Autores principales:	Botton, Jérémie, Semenzato, Laura, Jabagi, Marie-Joëlle, Baricault, Bérangère, Weill, Alain, Dray-Spira, Rosemary, Zureik, Mahmoud
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892225/ https://www.ncbi.nlm.nih.gov/pubmed/35234883 http://dx.doi.org/10.1001/jamanetworkopen.2022.0868

Ejemplares similares

Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study
por: Bouillon, Kim, et al.
Publicado: (2022)

Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines
por: Botton, Jérémie, et al.
Publicado: (2022)

Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines
por: Le Vu, Stéphane, et al.
Publicado: (2022)

Characteristics associated with the residual risk of severe COVID-19 after a complete vaccination schedule: A cohort study of 28 million people in France
por: Semenzato, Laura, et al.
Publicado: (2022)

Vaccine effectiveness against severe COVID-19 outcomes within the French overseas territories: A cohort study of 2-doses vaccinated individuals matched to unvaccinated ones followed up until September 2021 and based on the National Health Data System
por: Semenzato, Laura, et al.
Publicado: (2022)

A modified self‐controlled case series method for event‐dependent exposures and high event‐related mortality, with application to COVID‐19 vaccine safety
por: Ghebremichael‐Weldeselassie, Yonas, et al.
Publicado: (2022)

Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID‐19: A Nationwide Matched Population‐Based Cohort Study
por: Bouillon, Kim, et al.
Publicado: (2022)

Protection of COVID-19 Vaccination Against Hospitalization During the Era of Omicron BA.4 and BA.5 Predominance: A Nationwide Case–Control Study Based on the French National Health Data System
por: Semenzato, Laura, et al.
Publicado: (2023)

Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients
por: Semenzato, Laura, et al.
Publicado: (2021)

Stroke, Myocardial Infarction, and Pulmonary Embolism after Bivalent Booster
por: Jabagi, Marie-Joelle, et al.
Publicado: (2023)

8Association entre les vaccins COVID-19 à ARN messager et la survenue de myocardite et péricardite chez les personnes de 12 à 50 ans en France
por: Vu, S. Le, et al.
Publicado: (2022)

Design cas témoins apparié sur score de risque : un outil méthodologique original pour une étude de l'efficacité vaccinale et des conséquences médicales de l'hospitalisation pour COVID-19 en France.
por: Semenzato, L., et al.
Publicado: (2023)

Profiles of copper intrauterine devices and levonorgestrel intrauterine systems users in France in 2019: A national observational population‐based study
por: Roland, Noémie, et al.
Publicado: (2022)

3Estimation de l'impact de la vaccination sur le risque de formes graves de COVID-19 au sein des départements d'Outre-Mer à partir des données du Système national des données de santé (SNDS) - Résultats jusqu'au 30 septembre 2021
por: Semenzato, L., et al.
Publicado: (2022)

Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people
por: Semenzato, Laura, et al.
Publicado: (2021)

No association of low‐dose aspirin with severe COVID‐19 in France: A cohort of 31.1 million people without cardiovascular disease
por: Botton, Jérémie, et al.
Publicado: (2022)

Caractéristiques sociodémographiques et médicales associées au risque d’échec d'un schéma vaccinal deux doses contre la COVID-19 en France
por: Semenzato, L., et al.
Publicado: (2022)

Contribution of real-life studies in France during the COVID-19 pandemic and for the national pharmaco-epidemiological surveillance of COVID-19 vaccines
por: Zureik, Mahmoud, et al.
Publicado: (2023)

Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination
por: Iketani, Sho, et al.
Publicado: (2021)

Evaluation of the Incidence of Hematologic Malignant Neoplasms Among Breast Cancer Survivors in France
por: Jabagi, Marie Joelle, et al.
Publicado: (2019)

Risk of Hematologic Malignant Neoplasms after Postoperative Treatment of Breast Cancer
por: Jabagi, Marie Joelle, et al.
Publicado: (2019)

Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa
por: Gray, Glenda, et al.
Publicado: (2022)

Mandatory Infant Vaccinations in France During the COVID-19 Pandemic in 2020
por: Taine, Marion, et al.
Publicado: (2021)

Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COV2.S-associated VITT
por: Abou-Ismail, Mouhamed Yazan, et al.
Publicado: (2022)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines
por: Naranbhai, Vivek, et al.
Publicado: (2021)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
por: Barocci, Simone, et al.
Publicado: (2022)

Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester
por: Citu, Ioana Mihaela, et al.
Publicado: (2022)

Colonoscopy in France during the COVID-19 pandemic
por: Meyer, Antoine, et al.
Publicado: (2021)

Traitements du psoriasis et risque d’hospitalisation ou de décès pour COVID-19. Étude de cohorte à propos de 132 6312 patients atteints de psoriasis en France
por: Penso, Laetitia, et al.
Publicado: (2021)

Diminution drastique des mises en route de biomédicaments chez les patients atteints de psoriasis durant la pandémie de COVID-19 en France
por: Penso, Laetitia, et al.
Publicado: (2021)

Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study
por: Laanani, Moussa, et al.
Publicado: (2023)

Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data
por: Cari, Luigi, et al.
Publicado: (2021)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Utilisation des données du Système national des données de santé et/ou PMSI pour des études en lien avec la COVID-19 en France: bilan des publications scientifiques indexées dans Medline
por: Weill, A., et al.
Publicado: (2023)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_75lj9f2qhp9c95jbhag63j2r0s